Managing clinical trials during Coronavirus (COVID-19)

This guidance advises those involved in clinical trials on specific issues which may arise as a result of COVID-19, and what they are required to do. The MHRA will be as flexible and pragmatic as possible with regard to regulatory requirements for clinical trials during this time


Medicines and Healthcare products Regulatory Agency